MX2017007065A - Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia. - Google Patents

Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.

Info

Publication number
MX2017007065A
MX2017007065A MX2017007065A MX2017007065A MX2017007065A MX 2017007065 A MX2017007065 A MX 2017007065A MX 2017007065 A MX2017007065 A MX 2017007065A MX 2017007065 A MX2017007065 A MX 2017007065A MX 2017007065 A MX2017007065 A MX 2017007065A
Authority
MX
Mexico
Prior art keywords
isoindolin
oxoethyl
fluorophenyl
methyl
compositions
Prior art date
Application number
MX2017007065A
Other languages
English (en)
Inventor
Okuyama Masahiro
Luthringer Remy
Werner Sandra
Noel Nadine
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of MX2017007065A publication Critical patent/MX2017007065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación proporciona un nuevo polimorfo del Compuesto (I): (ver Fórmula) monoclorhidrato de 2-((1-(2-(4-fluorofenil)-2-oxoeti l) piperidin-4-il) metil) isoindolin-1-ona dihidratado, es decir, la Forma (A) del Compuesto (I) ·HCl · 2H2O. Se divulgan también composiciones farmacéuticas que comprenden la Forma (A) del Compuesto (I) ·HCl · 2H2O y métodos de tratamiento relacionados.
MX2017007065A 2014-12-02 2015-11-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia. MX2017007065A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US201562248071P 2015-10-29 2015-10-29
PCT/US2015/062985 WO2016089766A1 (en) 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Publications (1)

Publication Number Publication Date
MX2017007065A true MX2017007065A (es) 2017-12-18

Family

ID=54848909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007065A MX2017007065A (es) 2014-12-02 2015-11-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.

Country Status (26)

Country Link
US (6) US9458130B2 (es)
EP (2) EP3227273B1 (es)
JP (3) JP2018501217A (es)
KR (1) KR102620681B1 (es)
CN (2) CN107567444A (es)
AU (4) AU2015355226B2 (es)
BR (1) BR112017011555B1 (es)
CA (1) CA2968977A1 (es)
CL (2) CL2017001376A1 (es)
CO (1) CO2017005498A2 (es)
DK (1) DK3227273T3 (es)
EA (1) EA201791226A1 (es)
ES (1) ES2910528T3 (es)
HU (1) HUE058212T2 (es)
IL (3) IL280052B2 (es)
MX (1) MX2017007065A (es)
MY (1) MY185516A (es)
PE (1) PE20171646A1 (es)
PH (1) PH12017501007A1 (es)
PL (1) PL3227273T3 (es)
PT (1) PT3227273T (es)
SG (1) SG11201704332YA (es)
TW (1) TWI694069B (es)
UA (1) UA122780C2 (es)
WO (1) WO2016089766A1 (es)
ZA (1) ZA201703481B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3227273T (pt) 2014-12-02 2022-04-06 Minerva Neurosciences Inc Composições que compreendem 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratamento de esquizofrenia
KR20240005110A (ko) 2016-05-25 2024-01-11 미쓰비시 타나베 파마 코퍼레이션 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
US11464744B2 (en) * 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
MX2021002017A (es) * 2018-08-21 2021-04-28 Minerva Neurosciences Inc Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
EP4153209A1 (en) 2020-05-20 2023-03-29 The Board of Trustees of the University of Illinois Method for treating lysosomal storage diseases with histatin peptides
WO2023154927A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
WO1991006297A1 (en) 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
ES2291293T3 (es) 2000-02-29 2008-03-01 Mitsubishi Pharma Corporation Nuevos derivados amida ciclicos.
AU2002304784A1 (en) * 2001-03-26 2002-10-08 Novartis Pharma Gmbh Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
EP1891002B1 (en) 2005-06-06 2012-05-30 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
TWI520949B (zh) * 2010-07-20 2016-02-11 錫蘭尼克藥物有限公司 使用環醯胺衍生物治療σ受體介導之病症的方法
HRP20231446T1 (hr) * 2010-07-20 2024-03-01 Minerva Neurosciences, Inc. Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
BR112013023810A2 (pt) * 2011-03-17 2016-12-13 Lupin Ltd composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
PT3227273T (pt) * 2014-12-02 2022-04-06 Minerva Neurosciences Inc Composições que compreendem 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratamento de esquizofrenia
KR20240005110A (ko) 2016-05-25 2024-01-11 미쓰비시 타나베 파마 코퍼레이션 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
US11464744B2 (en) 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
MX2021002017A (es) 2018-08-21 2021-04-28 Minerva Neurosciences Inc Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.

Also Published As

Publication number Publication date
IL301320A (en) 2023-05-01
AU2015355226A1 (en) 2017-06-08
AU2020204286A1 (en) 2020-07-16
KR102620681B1 (ko) 2024-01-04
ES2910528T3 (es) 2022-05-12
NZ770365A (en) 2023-10-27
AU2015355226B2 (en) 2020-04-02
IL252347A0 (en) 2017-07-31
ZA201703481B (en) 2023-12-20
CL2021000044A1 (es) 2021-06-04
CA2968977A1 (en) 2016-06-09
EA201791226A1 (ru) 2017-09-29
US20230201184A1 (en) 2023-06-29
CN107567444A (zh) 2018-01-09
KR20170106310A (ko) 2017-09-20
IL280052B2 (en) 2023-09-01
DK3227273T3 (da) 2022-05-02
CO2017005498A2 (es) 2017-09-20
US10258614B2 (en) 2019-04-16
US10799493B2 (en) 2020-10-13
AU2023258386A1 (en) 2023-11-23
CL2017001376A1 (es) 2018-02-16
TWI694069B (zh) 2020-05-21
PL3227273T3 (pl) 2022-05-30
JP2020172531A (ja) 2020-10-22
AU2020204286B2 (en) 2021-06-17
IL280052A (en) 2021-03-01
US20160152597A1 (en) 2016-06-02
SG11201704332YA (en) 2017-06-29
US20180153871A1 (en) 2018-06-07
MY185516A (en) 2021-05-19
JP2018501217A (ja) 2018-01-18
EP3227273A1 (en) 2017-10-11
HUE058212T2 (hu) 2022-07-28
CN111110677A (zh) 2020-05-08
EP4063357A1 (en) 2022-09-28
TW201632511A (zh) 2016-09-16
BR112017011555A2 (pt) 2018-01-09
PT3227273T (pt) 2022-04-06
EP3227273B1 (en) 2022-02-09
US20210228561A1 (en) 2021-07-29
BR112017011555B1 (pt) 2023-10-03
US9458130B2 (en) 2016-10-04
UA122780C2 (uk) 2021-01-06
JP2022105159A (ja) 2022-07-12
AU2021229240B2 (en) 2023-08-24
IL252347B (en) 2021-01-31
IL280052B1 (en) 2023-05-01
US20200022968A1 (en) 2020-01-23
PH12017501007A1 (en) 2017-12-18
JP7069253B2 (ja) 2022-05-17
PE20171646A1 (es) 2017-11-13
AU2021229240A1 (en) 2021-10-07
US9730920B2 (en) 2017-08-15
US20170042877A1 (en) 2017-02-16
NZ732033A (en) 2023-10-27
WO2016089766A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
MX2017007065A (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.
PH12019500163A1 (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
ZA201701299B (en) Glycosidase inhibitors
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
MX2017009892A (es) Agente terapeutico contra el colangiocarcinoma.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AP2016009370A0 (en) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.
MX2018006329A (es) Agente terapeutico para cancer de mama.
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
PH12016501483A1 (en) P-substituted asymmetric ureas and medical uses thereof
CY1121909T1 (el) Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου
NZ759901A (en) Solid oral pharmaceutical compositions of dabigatran etexilate
NZ747821A (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof